source
- Spyre Therapeutics reports SPY072 fails psoriatic arthritis trial as Ideaya halts eye cancer studySpyre Therapeutics announced that its long‑acting anti‑TL1A candidate, SPY072, did not meet the primary endpoints in a psoriatic arthritis trial. The result adds to recent setbacks for Spyre in ot…
- FDA urges biosimilar makers to adopt alternatives to clinical efficacy trialsFDA's Office of Therapeutic Biologics and Biosimilars, led by director Sarah Yim, announced that the agency is working to help sponsors rely less on clinical efficacy studies when developing biosim…